Gufic Indore reaches EBITDA break-even, targets U.S. by FY28
Key highlights
- Gufic said Indore reached EBITDA break-even and made a positive contribution in Q2 FY27.
- Q2 FY27 revenue rose to Rs 288.4 crore from Rs 230.4 crore in Q2 FY26.
- Q2 FY27 EBITDA increased to Rs 49.7 crore from Rs 37.9 crore, with a 17.23% margin.
- Management expects inventory to decline from about Rs 370 crore to Rs 325 crore to Rs 330 crore by March 2027.
powered by IRIS

Gufic Biosciences Limited said its Indore facility reached earnings before interest, tax, depreciation and amortisation (EBITDA) break-even in Q2 FY27, contributing positively as company revenue rose to Rs 288.4 crore, while management’s stated expectation is to cater to the U.S. market by Q2 or Q3 FY28 after regulatory progress.
Know Gufic BioSciences inside out
Results, valuation, peers and who's buying, in one view.
Has Gufic's Indore plant reached EBITDA break-even?
Yes. Gufic said Indore achieved EBITDA break-even in Q2 FY27 and made a positive contribution during the quarter, although it had not yet covered depreciation and interest costs. Chief Financial Officer Devkinandan Roonghta said management expects the facility to cover those costs in Q4, which would be the next step beyond operating break-even.
The plant’s operating activity also advanced from Q1 FY27, with output higher across all four lines in Q2 FY27. The depot suite was ready for trials and media fills, the spray-dried route for a lipid-based antifungal was close to completion, and an injectable-emulsion format had completed scale-up. Gufic did not disclose Indore’s revenue, EBITDA amount or utilization rate.
Management said some Indore benefit contributed to Q2 FY27 revenue through India and rest-of-world markets that the facility can currently serve. It distinguished that contribution from the higher-end business and margin expansion expected from regulated markets. That distinction means the reported break-even was achieved before a disclosed U.S. commercial supply ramp.
When could Gufic begin U.S. supplies from Indore?
Management said it hopes Gufic can cater to the U.S. market by Q2 or Q3 FY28, subject to regulatory and customer-led product-launch progress. The U.S. Food and Drug Administration completed a pre-approval inspection at Indore following a partner’s product goal date, and Gufic said it submitted its response to three Form 483 observations within the stipulated period.
Gufic described the three observations as non-critical, but the call did not disclose product approval, a final inspection classification or a U.S. launch date. Management said the inspection encouraged other prospective customers awaiting line approvals to begin activity. The facility had also hosted audits by prospective U.S. and U.K. partners, without identifying customers, products or potential sales.
Management plans to introduce at least four additional molecules between November and March, with a possible total of four to six depending on technical discussions for the final two molecules. It said these additions would help qualify other Indore lines. A later comment referred to possible U.S. entry within three to six months, but management also called Q3 FY28 a worst-case outcome; the Q2 or Q3 FY28 statement is the more specific timeline disclosed.
What did Gufic report for Q2 FY27?
Gufic reported revenue from operations of Rs 288.4 crore in Q2 FY27, up from Rs 230.4 crore in Q2 FY26, while EBITDA increased to Rs 49.7 crore from Rs 37.9 crore. Profit before tax rose to Rs 31.5 crore from Rs 20.5 crore, and profit after tax increased to Rs 23.5 crore from Rs 14.9 crore.
EBITDA margin was 17.23% in Q2 FY27, compared with 16.45% a year earlier, while profit-after-tax margin rose to 8.15% from 6.47%. For the first half of FY27, revenue was Rs 549.2 crore against Rs 457.3 crore in the prior-year half, and EBITDA was Rs 96.9 crore against Rs 71.1 crore, lifting EBITDA margin to 17.64% from 15.455%.
Sequentially, management said Q2 FY27 EBITDA margin declined from 18.1% to 17.23%, or about 0.9 percentage points. Roonghta attributed the change to rupee depreciation raising imported active pharmaceutical ingredient costs, which could not immediately be passed through, and to increased domestic and international transportation costs. He said management expects margin normalization by Q4.
Got a follow-up? Ask IRIS
What will determine Indore's revenue and margin ramp?
Regulatory decisions, customer launch schedules and inventory required for validation batches will determine the pace of Gufic’s Indore ramp. For U.S. contract manufacturing work, management said customers own the abbreviated new drug applications and Gufic must hold engineering and exhibit batches until an inspection or product goal date. Those batches can be sold only after product approval.
Inventory was about Rs 370 crore in Q2 FY27, and management expects it to decline to Rs 325 crore to Rs 330 crore by March 2027. Gufic said it added Rs 40 crore to Rs 50 crore of inventory to protect supply continuity amid the U.S.-Iran war. It also expects validation stock to continue for regulated-market products, though management described the current inventory level as the peak.
For Europe, Gufic said audits had been completed and compliance submissions made, while certification or final regulatory acceptance remained pending. Management hopes to enter Europe by September 2027, using Indore as an additional site to existing Navsari prospects. Separately, it said registrations for 14 stock-keeping units across 22 to 23 countries were expected to be largely completed by March 2027, targeting about 156 marketing authorizations for those products.
Management said the selected products address a market of Rs 82.4 crore across the cited geographies and it targets a 10% to 15% share over time. It expects peak revenue from that registration programme to take three to four years, despite gradual annual penetration. Gufic also said it had spent about EUR 1.5 million to EUR 1.6 million on registrations, with most of that investment expected to be captured in FY27.
Conclusion
Indore’s Q2 FY27 EBITDA break-even establishes an operating contribution from a plant still progressing through product qualification, regulatory review and customer onboarding. Gufic’s consolidated revenue increased by Rs 58 crore year on year to Rs 288.4 crore, while the facility’s initial contribution came from India and rest-of-world business rather than a disclosed U.S. launch.
The next disclosed milestones are Indore covering depreciation and interest in Q4, the addition of at least four molecules between November and March, and inventory declining to Rs 325 crore to Rs 330 crore by March 2027. Management’s Europe target is September 2027, while U.S. supplies depend on regulatory and customer progress toward its stated Q2 or Q3 FY28 expectation.


